F10 and venous thromboembolism: FXa is strategically positioned at the junction of the intrinsic and extrinsic pathways and proximal to IIa in the coagulation cascade such that targeting fXa with new drugs can have profound effects on coagulation and venous thromboembolism risk [5–8].